These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11434622)

  • 21. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
    Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
    Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study.
    Wedemeyer H; Reimer J; Sandow P; Hueppe D; Lutz T; Gruengreiff K; Goelz J; Christensen S; Pfeiffer-Vornkahl H; Alshuth U; Manns MP
    Liver Int; 2017 Oct; 37(10):1468-1475. PubMed ID: 28247572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
    Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcome of chronic hepatitis C in patients treated with interferon: comparison between responders and non-responders.
    Morisco F; Marmo R; Iasevoli P; Sessa G; Tuccillo C; Del Vecchio Blanco C; Caporaso N
    Ital J Gastroenterol Hepatol; 1999; 31(6):454-8. PubMed ID: 10575561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The efficacy of interferon alfa treatment in chronic hepatitis C in relation to the serum concentration of RNA-HCV and the viral genotype].
    Hermida M; Castro A; López S; Vega P; Pedreira J
    An Med Interna; 1997 Oct; 14(10):500-5. PubMed ID: 9424139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Takayanagi M; Yoshioka K; Kakumu S; Iijima A; Urushihara A; Kiyosawa K; Okuda M; Hino K; Okita K
    Hepatology; 1998 May; 27(5):1394-402. PubMed ID: 9581697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.
    Gramenzi A; Andreone P; Fiorino S; Cammà C; Giunta M; Magalotti D; Cursaro C; Calabrese C; Arienti V; Rossi C; Di Febo G; Zoli M; Craxì A; Gasbarrini G; Bernardi M
    Gut; 2001 Jun; 48(6):843-8. PubMed ID: 11358906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.
    Larghi A; Tagger A; Crosignani A; Ribero ML; Bruno S; Portera G; Battezzati PM; Maggioni M; Fasola M; Zuin M; Podda M
    J Med Virol; 1998 May; 55(1):7-11. PubMed ID: 9580879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
    Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.
    Petta S; Di Marco V; Bruno S; Enea M; Calvaruso V; Boccaccio V; Rossi S; Craxì A; Cammà C
    Liver Int; 2016 Dec; 36(12):1765-1773. PubMed ID: 27164508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
    Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
    Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.